About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > PRODUCTS & SERVICES
  Biosimilars
  Small Molecules
  Branded Formulations
  Research Services
   
   Home
   
     
 

 
 

 

ALZUMAb is the World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for the treatment of Psoriasis in India.

- Excellent safety and efficacy profile with very low opportunistic   infection rates and longer remission period

- Offers a new treatment option for Psoriasis with a less   aggressive dosing regimen and a longer treatment free period,   ensuring better patient compliance and convenience

- Is an innovative affordable treatment option with a promise to   offer a better quality of life for the patient

- Will provide an effective biologic treatment solution to 1-2% of   Indian population suffering from Psoriasis

- ALZUMAb (Itolizumab) has demonstrated preclinical   and/clinical evidence in treating other autoimmune diseases   like rheumatoid arthritis, psoriatic arthritis and multiple   sclerosis.

- Biocon is committed to offering this novel anti-CD6 biologic   from India to patients across the globe


Inflammatory autoimmune diseases like Psoriasis, Rheumatoid Arthritis and Multiple Sclerosis require therapeutic intervention to modulate the immune system and alleviate disease symptoms. Autoimmune diseases are chronic in nature and patients require life long treatment. T-Cells found in the immune system which cause these diseases are a natural target for immunomodulation.

Itolizumab is the world’s 'first-in-class' humanized anti-CD6 monoclonal antibody (MAb) that has a unique mechanism of action (MOA) targeting the CD6 pathway. CD6 is a pan T-Cell marker involved in co-stimulation, adhesion and maturation of T-Cells, which have been found to play a leading role in autoimmune diseases. Itolizumab, by binding to CD6, down regulates T-Cell activation, causes reduction in synthesis of proinflammatory cytokines and possibly plays an important role by reducing T-Cell infiltration at sites of inflammation.

Emerging data shows that in addition to Th1, Th17 cells play a critical role in autoimmune diseases. Itolizumab is the world’s first anti-CD6 biologic addressing the Th17 pathway that has completed its 'Lab to Market' journey, making Biocon a front-runner in the race to develop biologics targeting the Th17 pathway.

Unlike other biologics like cytokine inhibitors which act downstream in the pro-inflammatory cascade, Itolizumab acts upstream inhibiting the formation of cytokines, resulting in lower infection rates and longer remission periods.

In addition to the Phase 3 TREAT-PLAQ study, two positive Phase 2a dose finding studies have been conducted one each in rheumatoid arthritis and psoriasis. A total of over 300 patients have been treated with Itolizumab, of these, about 100 patients have received the drug for 52 weeks with encouraging safety and tolerability profile. Itolizumab was approved by Drugs Controller General of India for treatment of Psoriasis in India in 2013.

Biocon has launched Itolizumab as ALZUMAbfor the treatment of psoriasis in India. It is the Second Novel Biologic from Biocon to be introduced for Indian patients.

   
   
 
  Watch video on:

ALZUMAb launched in India
Biocon's Break Through Innovation
 
 
  Photogallery
 
   
 
  Download Presentation
  Paradigm Changed for Psoriasis Treatment: pdf
  An Introduction to Novel Biologic for Psoriasis: pdf
   
 
  Click here for more information
  Medical Professional
  Patient Assistance
 
 
  Media Coverage
  Economic Times, Times of India, Business Standard...
   
 
  Medical Contact
 


Dr. Swaroop HS MBBS MD
Medical Affairs, Specialty Division
T: +91 80 67751623
E: swaroop.hs@biocon.com

   
  Send your queries to
  alzumab.patientcontact@biocon.com
   
  Medical Contact
  Dr. Swaroop HS MBBS MD
  swaroop.hs@biocon.com
  +91 80 67751623
 
  Medical Professional
 
  Patient Assistance
 
  Send your queries to
  Patient Contact
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved